Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN7075 · 1 trial · 1 indication
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose expansion
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Variety of mixed advanced solid tumor types |
| Dose Expansion A | EXPERIMENTAL | Triple Negative Breast Cancer (TNBC) |
| Dose Expansion B | EXPERIMENTAL | Cutaneous Squamous Cell Carcinoma (CSCC) |
| Dose Expansion C | EXPERIMENTAL | Non-Small Cell Lung Cancer (NSCLC) |
| Dose Expansion D | EXPERIMENTAL | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Dose Expansion E | EXPERIMENTAL | Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases |
| Dose Expansion F | EXPERIMENTAL | MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases) |
| Dose Expansion G | EXPERIMENTAL | Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI) |
| Dose Expansion H | EXPERIMENTAL | EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy |
| Dose Expansion I | EXPERIMENTAL | Third-line (3L) MSS-CRC with Active Liver Metastases |
| Dose Expansion J | EXPERIMENTAL | 3L MSS-CRC without Active Liver Metastases |
| Name | Type | Description |
|---|---|---|
| REGN7075 | DRUG | Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) |
| Cemiplimab | DRUG | Administered concomitantly Q3W by IV infusion or SC injection |
| Platinum-based doublet chemotherapy | DRUG | Administered IV Q3W |
| Bevacizumab | DRUG | Administered per protocol |
| Trifluridine-tipiracil | DRUG | Administered per protocol |
Key Inclusion Criteria: 1. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 2. Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol 3. Expansion Cohorts only: Is anti-Programmed cell Death protein-1 (PD-1)/Programmed cell D...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
REGN7075 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, where it is being studied in combination with cemiplimab for adult participants with advanced cancers.
REGN7075 targets EGFR and CD28. EGFR is a receptor tyrosine kinase often involved in cell growth, while CD28 is a costimulatory receptor on T cells. By targeting these proteins, REGN7075 is designed to modulate immune responses against tumors.
REGN7075 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
REGN7075 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness in patients with advanced solid tumors.
REGN7075 is being studied in a Phase 1 clinical trial with the identifier NCT04626635. This trial is titled 'A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers' and is currently active but not recruiting participants.
No, REGN7075 is not the same as cemiplimab. REGN7075 is a small molecule targeting EGFR and CD28, while cemiplimab is a separate drug that targets PD-1. In the clinical trial, REGN7075 is being studied in combination with cemiplimab for the treatment of advanced solid tumors.